Pharmacogenetic Implications for Clinical Practice of Smoking CessationTreatment

سال انتشار: 1401
محل انتشار: چهارمین کنگره ملی و اولین کنگره بین المللی دخانیات و سلامت
کد COI اختصاصی: THMED04_012
زبان مقاله: انگلیسی
تعداد مشاهده: 128

نویسندگان

Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of MedicalSciences, Bandar Abbas, Iran.

چکیده

This is expected smoking to reach ۱.۶–۱.۹ billion by ۲۰۲۵. Only ۱۵–۳۰% of smokers continue toabstain from smoking. Hence, various quit efforts are often required. There is extensive proof thatsmoking persistence is inherited, and are determined by a multifaceted interaction of polygenicand environmental risk factors. Tobacco smoking is thought to be a multifactorial behaviourthrough genetic and environmental elements. It was shown that genetic factors justify roughly ۴۰–۷۵% of the variation in smoking initiation, ۷۰–۸۰% of the variation in smoking preservation,around ۵۰% of the difference in cessation achievement and ۳۰–۵۰% of the difference in risk ofwithdrawal symptoms. Variations in two comprehensive classes of candidate genes weresuggested to contribute to smoking behaviour, including; genes that likely impact the response tonicotine (nicotine metabolism, nicotinic receptors) and genes that may influence to addictivebehaviour because of key neurotransmitter pathways (dopamine and serotonin). Sincepharmacogenetic therapies for smoking cessation are usually administered at the variation of thepathways involved in smoking addiction, perhaps, this will influence the efficacy of these smokingcessation therapies as an emerging approach for individually tailored smoking cessation treatmentbased on genetic background. Therefore, a profile of genetic variants in these smoking-relatedpathways could possibly be used to expect earlier which smoking cessation therapy is likely to bemost effective. Perspective of the role that inherited variation plays in response topharmacotherapy could help physicians to personalize treatment type, dose, and duration based ongenotype, thus reducing adverse reactions, improving treatment compliance, and maximizingpharmacotherapy effectiveness.

کلیدواژه ها

Smoking, Cessation, Pharmacogenetic, Pharmacotherapy, Genes

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.